Diagnostics R&D Engines:
Redefining Diagnostics for
a Healthier Future
We are committed to revolutionizing diagnostics through innovative research and development projects that deliver accuracy, efficiency, and accessibility. Our comprehensive diagnostic R&D portfolio spans across critical categories, each designed to address the diverse needs of healthcare providers and patients alike.
Current R&D Focus area
CLIA Analyzers
Our research focuses on advancing Chemiluminescence Immunoassay (CLIA) analyzers to offer high-performance solutions for laboratory diagnostics. We aim to design systems that ensure accuracy, speed, and reliability while being scalable for a wide range of clinical applications, from routine testing to complex disease diagnostics.
- Developing high-throughput systems with rapid turnaround times.
- Innovating seamless integration with laboratory information systems (LIS).
- Enhancing sensitivity and specificity through advanced assay technologies.
CLIA Assays
Amorph's R&D efforts include expanding our CLIA assay portfolio with a broad range of diagnostic tests for detecting biomarkers across various disease areas. Our focus is on creating assays that deliver unparalleled accuracy and reproducibility.
- Early disease detection and monitoring through novel biomarkers.
- Customizing assays to address specific clinical and research needs.
- Developing comprehensive panels for precision diagnostics.
Point-of-Care Diagnostics
Our R&D team is dedicated to advancing Point-of-Care (POC) diagnostic technologies that bring testing closer to patients. We are developing portable and user-friendly devices to empower healthcare providers in remote and resource-limited settings.
- Rapid testing innovations for infectious diseases, cardiac markers, and more.
- Immediate-result technologies to guide treatment decisions.
Molecular Diagnostics
We are investing in cutting-edge R&D for molecular diagnostics, leveraging technologies like PCR and next-generation sequencing to provide precise and reliable results for detecting genetic disorders, infectious diseases, and cancer.
- Researching early detection of genetic mutations and oncogenic markers.
- Pioneering high-sensitivity and specificity methods for advanced clinical insights.
- Advancing comprehensive pathogen identification for infectious diseases.
Sample Preparation Solutions
Amorph’s R&D in sample preparation focuses on developing efficient and reliable systems and reagents to simplify and optimize the diagnostic workflow, ensuring high-quality results.
- Automating extraction and purification processes for DNA, RNA, and proteins.
- Ensuring compatibility with a wide range of downstream diagnostic applications.
- Innovating solutions for high-throughput and single-sample workflows.
Our Impacts
- Advancing Early Disease Detection: Developing innovative tools like CLIA assays and molecular diagnostics to enable timely identification and monitoring of diseases.
- Empowering Healthcare Providers: Providing high-performance systems and user-friendly point-of-care devices for accurate, rapid, and efficient diagnostics.
- Enhancing Accessibility: Expanding diagnostic capabilities in underserved and remote regions with portable and scalable solutions.
- Driving Precision Medicine: Offering customizable assays and advanced molecular tools for targeted and individualized patient care.
- Promoting Sustainability: Integrating eco-friendly practices in R&D and production to minimize environmental impact.
- Improving Patient Outcomes: Delivering accurate and reliable diagnostic solutions that guide effective treatment and foster better healthcare decision-making globally.
We Are Empowering Healthcare Through Diagnostic Innovation.
we envision a world where diagnostic advancements drive healthcare innovation. By integrating cutting-edge research, precision, and sustainability, our R&D projects aim to empower healthcare providers and improve patient outcomes globally.
